INTRODUCTION: The inflammatory bowel diseases are chronic illnesses that significantly affect the quality and patients life expectancy. There is clinical polymorphism and the therapeutic approach has been modified in recent years. AIM: To re-analyze the profile of outpatient patients studying the behavior of the disease, its prevalence and therapeutic approach. METHODS: Was conducted a cross-sectional study of the last 2010 update database of patients with inflammatory bowel disease. The items analyzed were age and sex of patients, type of disease (ulcerative colitis or Crohn's disease), disease location, type of medication used, and whether patients were symptomatic or asymptomatic at the last visit. RESULTS: In a total of 171 patients women were found to be predominant (60.8%) and the mean age was 42.3, ranging from 16 to 84 years. Regarding the type of inflammatory disease, ulcerative colitis was more prevalent (58.5%). The most common locations on ulcerative colitis were pancolitis and rectitis, both with 26% (n = 26). In Crohn's disease ileocolic location was the most prevalent, with 47.9% (n = 34), followed by colonic 25.4% (n = 18). Monotherapy was the most used, accounting for 54.4% of patients, the immunosuppressive drugs were the most frequently used (35.5%). The combination of drugs was necessary in 36.3% of cases, being the most frequent combination with systemic salicylate in 33.9%. In patients with ulcerative colitis 82% were using salicylates, whether local or systemic. In Crohn's disease 57.7% were taking immunosuppressive drugs. In relation to the disease in the last visit, 71.3% of patients were asymptomatic. CONCLUSION: The ulcerative colitis was slightly more prevalent than Crohn's disease, pancolitis and rectitis being the most common locations. In Crohn's disease ileocolic location was the most common followed by colonic. Monotherapy immunosuppressive regimen was the most popular. Most of the patients were asymptomatic at last visit.
Crohn disease; Ulcerative colitis; Epidemiology; Therapeutics
